REG - Goldman Sachs & Co. Avadel Pharma plc - 38.5b - AVADEL PHARMACEUTICALS PLC

Goldman SachsAnnouncement

Yesterday 15:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251212:nRSL4405La&default-theme=true

RNS Number : 4405L  Goldman Sachs & Co. LLC  12 December 2025

 
FORM 38.5(b)

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNISED INTERMEDIARY STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

 

1. KEY INFORMATION

 

 Name of exempt principal trader                                          GOLDMAN SACHS & CO. LLC
 Company dealt in                                                         AVADEL PHARMACEUTICALS PLC
 Class of relevant security to which the dealings being disclosed relate  USD 0.01 ordinary shares
 (Note1)
 Date of dealing                                                          11 December 2025

 

2. INTERESTS AND SHORT POSITIONS

 

(a) Interests and short positions (following dealing) in the class of relevant security dealt in  (Note 2)

 

                                              Long               Short
                                              Number     (%)     Number   (%)
 (1) Relevant securities                      1,023,742  (1.05)  504,894  (0.51)
 (2) Derivatives (other than options)         55,705     (0.05)  63,843   (0.06)
 (3) Options and agreements to purchase/sell  0          (0.00)  0        (0.00)
 Total                                        1,079,447  (1.10)  568,737  (0.58)

 

(b) Interests and short positions in relevant securities of the company, other than the class dealt in  (Note 2)

 

 Class of relevant security:                  Long         Short
                                              Number  (%)  Number  (%)
 (1) Relevant securities
 (2) Derivatives (other than options)
 (3) Options and agreements to purchase/sell
 Total

 

3.    DEALINGS (Note 3)

(a) Purchases and sales

 

 Purchase/sale                 Number of relevant securities  Price per unit  (Note 4)
 Purchase                      100                            21.3850 USD
 Purchase                      100                            21.3850 USD
 Purchase                      12                             21.3850 USD
 Purchase                      100                            21.3875 USD
 Purchase                      100                            21.3875 USD
 Purchase                      100                            21.3900 USD
 Purchase                      200                            21.3900 USD
 Purchase                      100                            21.3900 USD
 Purchase                      100                            21.3900 USD
 Purchase                      100                            21.3900 USD
 Purchase                      100                            21.3900 USD
 Purchase                      100                            21.3900 USD
 Purchase                      100                            21.3900 USD
 Purchase                      64                             21.3900 USD
 Purchase                      100                            21.3900 USD
 Purchase                      84                             21.3900 USD
 Sale (Loan New)               4,252                          N/A
 Sale (Borrow Partial Return)  58,200                         N/A
 Sale (Borrow Partial Return)  57,400                         N/A
 Purchase (Borrow New)         1,098                          N/A
 Sale (Borrow Full Return)     1,098                          N/A
 Purchase (Loan Full Return)   3,363                          N/A
 Purchase (Borrow New)         1,098                          N/A
 Sale (Borrow Partial Return)  27                             N/A
 Sale (Loan New)               889                            N/A
 Purchase (Loan Full Return)   889                            N/A

 

(b) Derivatives transactions (other than options transactions)

 

 Product name, e.g. CFD  Nature of transaction  (Note 5)   Number of relevant securities  (Note 6)   Price per unit  (Note 4)
 CFD                     Reducing a long position          587                                       21.4248 USD
 SWAP                    Opening a short position          84                                        21.4800 USD
 SWAP                    Reducing a short position         84                                        21.4800 USD

 

(c) Options transactions in respect of existing relevant securities

 

(i) Writing, selling, purchasing or varying

 

 Product name,e.g. call option  Writing, selling,  purchasing, varying etc.   Number of securities to which the option relates  (Note 7)   Exercise price  Type, e.g. American, European etc.  Expiry date  Option money paid/received per unit  (Note 4)

 

(ii)            Exercising

 

 Product name,e.g. call option  Number of securities  Exercise price per unit  (Note 4)

 

(d)            Other dealings (including transactions in respect of new securities)  (Note 3)

 

 Nature of transaction  (Note 7)   Details  Price per unit (if applicable)  (Note 4)

 

4. OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 Full details of any agreement, arrangement or understanding between the person
 disclosing and any other person relating to the voting rights of any relevant
 securities under any option referred to on this form or relating to the voting
 rights or future acquisition or disposal of any relevant securities to which
 any derivative referred to on this form is referenced.  If none, this should
 be stated.
 NONE

 

Is a Supplemental Form 8 attached? (Note 9)        YES

 

 Date of disclosure                            12 December 2025
 Contact name                                  Papa Lette and Andrzej Szyszka
 Telephone number                              +33(1) 4212 1459 / +48(22) 317 4817
 Name of offeree/offeror with which connected  AVADEL PHARMACEUTICALS PLC
 Nature of connection (Note 9)                 Advisor to Offeree

 

SUPPLEMENTAL FORM 38.5(b)

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DETAILS OF OPEN POSITIONS

 

OPEN POSITIONS (Note 1)

 

 Product name,e.g. call option  Written or purchased  Number of relevant securities to which the option or derivative relates  Exercise price (Note 2)  Type, e.g. American, European etc.  Expiry date
 Swap                           Sold                  84                                                                       0.0000                   N/A                                 13/03/2026
 Swap                           Purchased             33,762                                                                   0.0000                   N/A                                 20/01/2026

 

Notes

1. Where there are open option positions or open derivative positions (except
for CFDs), full details should be given. Full details of any existing
agreements to purchase or to sell must also be given on this form.

2. For all prices and other monetary amounts, the currency must be stated.

For full details of disclosure requirements, see Rules 8 and 38.5 of the
Rules. If in doubt, consult the Panel.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ITPFFAFLEEISEEE



            Copyright 2019 Regulatory News Service, all rights reserved